Circulating Tumor DNA Shows Promise for Guiding Immunotherapy in Lung Cancer
Study of 177 patients with limited-stage small cell lung cancer demonstrates ctDNA's potential to personalize consolidation immunotherapy decisions.
Category: Lung Cancer
Lung Cancer
Latest
Lung Cancer
Latest
Lung Cancer Test Differentiates Malignant and Benign Nodules
The Nu.Q Cancer Test distinguished between malignant and benign pulmonary nodules detected by LDCT scans in suspected lung cancer.
Lung Cancer
Latest
New Blood Test Detects Drug-Induced Tissue Damage in Cancer Patients Early
A blood test identifies early lung damage in cancer patients taking antibody–drug conjugates, offering an alternative to imaging scans.
DELFI Diagnostics Taps New CFO
Summary: DELFI Diagnostics appointed Thomas Russo as its new CFO to support the company’s...
Read More
AI-Powered Digital Pathology Platform Aids Lung Cancer Diagnosis
A new AI-driven digital pathology platform enables fully automated, rapid, and accurate analysis of lung cancer tissue.
Read More
Open Comment Period to Revise Molecular Testing Guidelines in Lung Cancer Treatment Announced
Several diagnostic associations announced the open comment period for the revised 2018 guideline on molecular testing for lung cancer.
Read More
New Test Influences First-Line Therapy Decisions for Metastatic NSCLC Patients
A new study from OncoHost reveals that its PROphetNSCLC test impacts oncologists’ first-line treatment decisions for metastatic NSCLC.
Read More
Development of Breath Test for Lung Disease is Underway
Researchers have developed a potential exhaled-breath test for lung diseases by successfully collecting lung biomarkers from human breath.
Read More
AI Blood Test Reliably Identifies Lung Cancer
Researchers have developed an AI-powered liquid biopsy to identify lung cancer earlier through DNA fragment patterns in blood.
Read More
DELFI Diagnostics’ Blood Test Validated for Early Lung Cancer Detection
DELFI’s blood-based Lung test has been clinically validated to enhance early detection of lung cancer, demonstrating high sensitivity.
Read More
PROphet Platform’s Predictive Ability to be Demonstrated
OncoHost will highlight the PROphet platform’s capability to predict benefits from therapies across various cancers.
Read More
DELFI Collaborates with Hospital System to Improve Lung Cancer Screening
OSF HealthCare will use DELFI’s FirstLook Lung blood test to enhance lung cancer screening rates and early detection efforts.
Read More
CAP Publishes Guideline for PD-L1 Testing of Lung Cancer Patients
CAP developed recommendations for testing immunotherapy biomarkers, such as PD-L1 and TM), in patients with NSCLC.
Read More
Nucleix’s New Assay May Differentiate Small Cell Lung Cancer Subtypes
Nucleix will present data that demonstrates the potential of a PCR assay to accurately differentiate between small cell lung cancer subtypes.Â
Read More
Study Demonstrates Clinical Validity of OncoHost’s NSCLC Test
The test guides first-line treatment selection by identifying individuals with the highest likelihood of benefit from PD-1/PD-L1 inhibitors
Read More
Noninvasive Testing Key to Id’ing Lung Cancer
New noninvasive diagnostic solutions for lung cancer being developed function as a complement to LDCT imaging.
Read More
New Epigenomic Technology Platform Predicts Immunotherapy Response in NSCLC Patients
The epigenomic technology platform predicts and monitors immunotherapy responses for patients with non-small cell lung cancer (NSCLC).
Read More
New ChromaCode Collaboration to Improve NSCLC Biomarker Testing Access
ChromaCode will collaborate with Tennessee Oncology to test the performance of ChromaCode’s HDPCR NSCLC biomarker assay.Â
Read More